Sawgrass Asset Management LLC Reduces Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Sawgrass Asset Management LLC decreased its position in IQVIA Holdings Inc. (NYSE:IQV) by 6.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 50,539 shares of the medical research company’s stock after selling 3,595 shares during the period. Sawgrass Asset Management LLC’s holdings in IQVIA were worth $9,931,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of IQV. Great Lakes Retirement Inc. raised its holdings in IQVIA by 6.2% during the 4th quarter. Great Lakes Retirement Inc. now owns 3,055 shares of the medical research company’s stock valued at $600,000 after acquiring an additional 179 shares during the period. Compound Global Advisors LLC bought a new stake in IQVIA during the 4th quarter valued at $334,000. Peterson Wealth Services raised its holdings in IQVIA by 19.6% during the 4th quarter. Peterson Wealth Services now owns 1,860 shares of the medical research company’s stock valued at $366,000 after acquiring an additional 305 shares during the period. Summit Trail Advisors LLC raised its holdings in IQVIA by 46.3% during the 4th quarter. Summit Trail Advisors LLC now owns 1,855 shares of the medical research company’s stock valued at $365,000 after acquiring an additional 587 shares during the period. Finally, Savant Capital LLC bought a new stake in IQVIA during the 4th quarter valued at $210,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Activity at IQVIA

In other news, Director John G. Danhakl purchased 1,275 shares of IQVIA stock in a transaction that occurred on Tuesday, December 3rd. The stock was bought at an average price of $200.58 per share, with a total value of $255,739.50. Following the completion of the transaction, the director now directly owns 1,275 shares of the company’s stock, valued at approximately $255,739.50. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.60% of the stock is owned by insiders.

IQVIA Price Performance

IQV stock opened at $197.64 on Thursday. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The firm has a 50-day moving average of $200.77 and a 200 day moving average of $218.81. The company has a market cap of $35.87 billion, a P/E ratio of 26.35, a PEG ratio of 2.25 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.81.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.81 EPS for the current year.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft lowered their target price on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a report on Friday, November 1st. StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, November 28th. TD Cowen decreased their price target on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, November 1st. The Goldman Sachs Group decreased their price target on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Finally, Truist Financial reiterated a “buy” rating and issued a $263.00 target price (up from $261.00) on shares of IQVIA in a research report on Monday. Five investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and a consensus target price of $251.67.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.